Panacos Pharmaceuticals (OTC: PANC.DL)
Panacos Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Panacos Pharmaceuticals Company Info
Panacos Pharmaceuticals, Inc. engages in the discovery and development of small-molecule oral drug which is designed to treat human immunodeficiency virus and other major human viral diseases. Its product candidate, bevirimat, which works by a novel mechanism of action called maturation inhibition. The company was founded by Graham Allaway in December 1992 and is headquartered in Watertown, MA.
News & Analysis
So-So Results From Panacos
Investors are discouraged after it releases the latest data for its top drug.
Making Cents in Penny Stocks
Are they cheap for a reason, or are they overlooked investment opportunities?
Better Late Than Never for Panacos
Panacos announces new data for its lead drug.
Stop Dragging, Panacos
The company announces another slight delay with its lead drug.
The CEO Who Battles HIV
An interview with Panacos Pharmaceuticals CEO Alan Dunton.
Panacos' Plans
Panacos gives guidance for the remainder of the year.
Get Ready for the Bounce
Who's fallen hardest? Who can bounce highest?
Panacos Validates Itself
Panacos releases more clinical trial results for an exciting drug.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.